1. Home
  2. Vol 54, No 1 (2022)
  3. Soelistijo

Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting

Soebagijo Adi Soelistijo, Andi Makbul Aman, Hendra Zufry, Agung Pranoto, Achmad Rudijanto, Mohamed Hassanien

Abstract


Background: Sulfonylureas (SUs) have been widely used in many countries for T2DM treatment. Gliclazide is one of the SUs with the lowest risk of hypoglycemia; however, the safety and effectiveness of gliclazide MR during Ramadan has not yet been reported in Indonesia. This study aimed to assess safety, efficacy, and tolerability of gliclazide modified release (MR) during Ramadan fasting. Methods: The study was a part of DIA-RAMADAN study, a prospective observational study with subjects of T2DM patients aged >18 years, who had either controlled or sub-optimally controlled blood glucose level, performed Ramadan fasting. Subjects had been treated with gliclazide MR for at least 90 days prior the study, and were examined for their body mass index (BMI), fasting plasma glucose (FPG) and HbA1c levels 6 to 8 weeks before Ramadan (V0) and 4 to 6 weeks after the end of Ramadan (V1). Results: Out of 198 subjects participating in the study, there were only two subjects (1.0%) who reported symptomatic HEs (either confirmed or not confirmed) and no severe HEs had been reported. There were no significant changes in HbA1c and FPG levels (p>0.05). Interestingly, there was a reduction of bodyweight (-0.4kg) from pre- to post-Ramadan (p < 0.001). Almost no subjects reported discontinuation of gliclazide MR throughout the entire study; however, there was one subject who reported a change of diabetic treatment into diet only. Conclusion: gliclazide MR is safe, well tolerated and can maintain glycemic control effectively for Indonesian patients with T2DM who perform Ramadan fasting.


Keywords


type 2 diabetes mellitus; diabetes mellitus; gliclazide MR; DIA-RAMADAN; Indonesia

References


Pew Researcher Center. The future of the global Muslim population. Projections for 2010-2030. Washington: Pew Research Center. 2011.

Indonesian Ministry of Health. Survey Kesehatan Rumah Tangga (SKRT) 2018. BALITBANGKES DEPKES 2018.

International Diabetes Federation., IDF Diabetes Atlas. Brussels, Belgium. 2017.

Lee JY, Wong CP, Tan CSS, Nasir NH, Lee SWH. Type 2 diabetes patient’s perspective on Ramadan fasting: a qualitative study. BMJ Open Diab Res Care. 2017;5:e000365.

Iskandar WJ, Handjaja CT, Salama N, Anasy N, Ardianto MF, Kusumadewi D. Evidence-based case report: acute diabetic complication risks of Ramadan fasting in type 2 diabetics. Acta Med Indones-Indones J Intern Med. 2013;45(3):235-39.

Al Sifri S, Basiounny A, Echtay A, Al Omari M, HarmanBoehm I, Kaddaha G, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: A randomised trial. Int J Clin Pract. 2011;65:1132–40.

Cholil AR, Lindarto D, Pemayun TGD, Wisnu W, Kumala P, Puteri HHS. DiabCare Asia 2012: diabetes management, control, and complications in patients with type 2 diabetes in Indonesia. Med J Indones. 2019;28(1):47-56.

Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: The VIRTUE study. Int J Clin Pract. 2013;67:957–63.

Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: A randomized, pragmatic study. Curr Med Res Opin. 2012;28:1289–96.

Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: The STEADFAST study. Vasc Health Risk Manag. 2014;10:319–26.

Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: practical guidelines. Diabetes Res Clin Pract. 2017;126:303–16.

Perkeni. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. Jakarta: PB Perkeni. 2019.

International Hypoglycemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diab Care. 2017;40:155–7.

Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–8.

Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the US: real-world evidence in patients newly diagnosed with type 2 diabetes. Diab Care. 2018;41(1):69–78.

Aravind SR, Al Tayeb K, Ismail SB, Shehadeh N, Kaddaha G, Liu R, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: A fivecountry observational study. Curr Med Res Opin. 2011;27:1237–42.

Ibrahim M, Abu Al Magd M, Annabi A, Assaad-Khalil S, Ba-Essa EM, Fahdil I et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care. 2015;3:e000108.

Hassanein M, Al Sifri S, Shaikh S, Raza SA, Akram J, Pranoto A et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020;163:108154.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.